

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) Publication number : **0 474 580 A2**

(12)

EUROPEAN PATENT APPLICATION

(21) Application number : **91610063.9**

(51) Int. Cl.⁵ : **A61K 31/34**

(22) Date of filing : **16.08.91**

(30) Priority : **06.09.90 DK 2132/90**

(43) Date of publication of application :
11.03.92 Bulletin 92/11

(84) Designated Contracting States :
AT BE CH DE DK FR GB IT LI LU NL SE


(71) Applicant : **H. LUNDBECK A/S**
Ottoliavej 7-9
DK-2500 København-Valby (DK)

(72) Inventor : **Tanaka, Yoshiaki**
1-2-10 Nakanishi
Kumagaya-shi, Saitama 360 (JP)
Inventor : **Kobayashi, Naomi**
1643 Kuge
Kumagaya-shi, Saitama 360 (JP)
Inventor : **Kurimoto, Tadashi**
1740-10 Mochida
Gyouda-shi, Saitama 361 (JP)
Inventor : **Ikeda, Yugo**
1-2-2-104 Kakinokizaka
Meguro-ku, Tokyo 152 (JP)

(74) Representative : **Petersen, John Meidahl**
c/o H. Lundbeck A/S Patent Department
Ottoliavej 7-9
DK-2500 Copenhagen-Valby (DK)

(54) Use of 1-[3-(dimethylamino)propyl]-1-phenylphthalenes for the treatment of cerebrovascular disorders.

(57) 1-[3-(dimethylamino)propyl]-1-phenylphthalanes of the general formula




Formula I

wherein R¹ and R² each are selected from the group consisting of halogen, trifluoromethyl, cyano and R-CO-, wherein R is an alkyl radical, or a pharmaceutically acceptable acid addition salt thereof, are useful in the treatment of dementia and cerebrovascular disorders and for inhibiting platelet aggregation in patients in need thereof.

EP 0 474 580 A2

The present invention relates to the use of a class of 1-[3-(dimethylamino)propyl]-1-phenylphthalanes for the manufacture of medicaments for the treatment of dementia and cerebrovascular disorders and for inhibiting platelet aggregation.

US patent No. 4,136,193 relates to 1-[3-(dimethylamino)propyl]-1-phenylphthalanes having the general formula



wherein R¹ and R² each are selected from the group consisting of halogen, trifluoromethyl, cyano and R-CO-, wherein R is an alkyl radical with from 1 to 4 C-atoms inclusive, and acid addition salts thereof with pharmaceutically acceptable acids.

Said compounds are described to be selective, centrally active serotonin (5-hydroxytryptamine; 5-HT) reuptake inhibitors and accordingly to have antidepressant activities. One of the tests used to show such activities was inhibition of ¹⁴C-5-HT uptake in rabbit blood platelets *in vitro*. The compound of Formula I wherein R¹ is a cyano group and R² is a fluorine atom is the known antidepressant citalopram, the antidepressant activity of which has been reported in several publications, eg. J. Hyttel, *Prog. Neuro-Psychopharmacol. & Biol. Psychiat.*, **1982**, 6, 277-295 and A. Gravem, *Acta Psychiatr. Scand.*, **1987**, 75, 478-486. A method of and intermediates for the preparation of citalopram are described in US Patent No 4,650,884 and methods of preparing the individual enantiomers of citalopram are disclosed in US Patent No 4,943,590.

Biochemical postmortem investigations of patients with Alzheimer's disease have shown hypofunction of the serotonin nervous system in the brain (D.M. Bowen et al., *J. Neurochem.*, **1983**, 41, 266-272). It is also known that depression is one of the major symptoms in Alzheimer's disease, and citalopram has been reported to be effective against depression associated with Alzheimer's disease (C.G. Gottfries, *Psychopharmacology*, **1988**, 96, 45 (Suppl.)). A study of a group of patients with moderate dementia of Alzheimer's type (AD/SDAT) or multi-infarct dementia (MID) has shown significant improvements in emotional lability, motivation, confusion, fear, panic, irritation, reduced mood and restlessness, whereas citalopram did not appear to have effect on intellectual functions (Nyth, A.L. et al. "The effect of citalopram in dementia disorders", presentation at CINP, August 1988; subsequently reported in Nyth, A.L. and Gottfries, C.G., "The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders. A nordic multicentre study." *Br. J. Psychiat.*, **1990**, 157, 894-901). Later controlled studies showed that treatment with citalopram caused no significant improvement on emotional disturbances in patients with vascular dementia (VD, incl. MID) (Nyth, A.L. et al. "The efficacy of citalopram in treatment of emotional disturbances in dementia disorders", *ECNP Abstract 1989*, Sweden, 79).

It has also been described that certain 5-HT_{1A} agonists show effect in the treatment of *Apoplexia cerebri* (Danish Patent Application No 4616/89).

Cerebrovascular disorders, such as ischemia which are triggered by cerebral infarction, cerebral hemorrhage, cerebral arteriosclerosis, subarachnoid hemorrhage, cerebral thrombosis, cerebral embolism, and other diseases are of increasing importance among the population and there is a great demand for effective and safe drugs for the treatment of such disorders and the sequelae of such disorders. A particular problem is dementia not only caused by cerebrovascular disorders but also dementia of other genesis.

Surprisingly, it has now been found that the compounds of the above Formula I show improving effects on cerebrovascular disorders, in particular ischemia, and the brain damage, and the impairment of memory functions in connection therewith and that they show inhibiting action on platelet aggregation. Furthermore, the compounds of the general Formula I have been found to present anti-amnesic effect and to improve cognitive function in elderly depressed patients having concomitant dementia, ie not only dementia of cerebrovascular origin, but also dementia as a result of chronic organic reactions, such as neurodegenerative disorders.

Accordingly, the present invention relates to the use of a compound of the above Formula I for the manufacture of medicaments for the prevention or treatment of senile dementia and of cerebrovascular disorders and for the inhibition of platelet aggregation.

Senile dementia may be senile dementia of any genesis such as neurodegenerative, traumatic, cerebrovascular, anoxic, etc, i.e. dementia of Alzheimer's type, multi-infarct dementia and vascular dementia, etc.

Cerebrovascular disorders are brain damages caused by cerebral infarction, cerebral hemorrhage, cerebral arteriosclerosis, subarachnoid hemorrhage, cerebral thrombosis, cerebral embolism, or the like, e.g. ischemia, and the psychological and neurological sequelae of such damages.

The use of the optical isomers of the compounds of general Formula I and their mixtures, including racemic mixtures thereof, is embraced by the invention.

The compound of general Formula I may be used as the free base or as a pharmacologically acceptable acid addition salt thereof. As acid addition salts such salts formed with organic or inorganic acids may be used. Exemplary of such organic salts are those with maleic, fumaric, benzoic, ascorbic, embonic, succinic, oxalic, bis-methylenesalicylic, methanesulfonic, ethanedisulfonic, acetic, propionic, tartaric, salicylic, citric, gluconic, lactic, malic, mandelic, cinnamic, citraconic, aspartic, stearic, palmitic, itaconic, glycolic, p-amino-benzoic, glutamic, benzene sulfonic and theophylline acetic acids, as well as the 8-halotheophyllines, for example 8-bromotheophylline. Exemplary of such inorganic salts are those with hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric and nitric acids.

An appropriate oral dose of the compound of general Formula I is 1-100mg/day p.o..

Due to the inhibition of platelet aggregation the medicaments obtained in accordance with the invention are useful in the treatment and/or prevention of microcirculation disturbances in the brain resulting from the above cerebral conditions or from venous or arterial thrombosis, or elsewhere in the body resulting from venous or arterial thrombosis or related conditions.

In view of the improving effects on cognitive function and on brain damages and of the platelet aggregation inhibiting effects now found as well as of the known effects on 5-HT uptake, the medicaments obtained in accordance with the present invention are useful in the treatment of senile dementia and cerebrovascular disorders, and the sequelae of cerebrovascular disorders such as psychiatric symptoms, e.g. anxiety, depression, loss of memory, hypobulia, restlessness, dementia, hallucinations, delusions, disturbances of consciousness, hypochondriac tendency, insomnia, excitation, garrulity, hyperkinesia, deliriums, and disturbances of orientation, neurological symptoms, eg. alalia, and hypodynamia, and subjective symptoms, eg. headache, dizziness, feeling of numbness, feeling of stiffness in the shoulder, feeling of exhaustion and heavy feeling in the head.

Additionally they have the further advantage of a very good safety profile.

A preferred compound of Formula I is citalopram.

The medicaments manufactured in accordance with the present invention are particularly useful in the treatment or prevention of ischemia in the brain and especially of dementia caused by ischemia.

Due to the pharmacological profile the medicaments manufactured in accordance with the present invention are especially useful in elderly patients.

Citalopram may be prepared by the methods disclosed in US patent No 4,650,884 and the other compounds used in accordance with the invention may be prepared analogously or by the methods of US patent No. 4,136,193. The individual enantiomers of citalopram may be prepared as described in US patent No. 4,943,590 and enantiomers of the other compounds of Formula I may be prepared by similar methods.

The acid addition salts of the compounds may be prepared by methods known in the art. The base is reacted with either the calculated amount of acid in a water miscible solvent, such as acetone or ethanol with subsequent isolation of the salt by concentration and cooling or with an excess of the acid in a water immiscible solvent, such as ethylether, ethylacetate or dichloromethane, with the salt separating spontaneously.

The medicaments prepared in accordance with the invention may be administered in any suitable way and in any suitable form, for example orally in the form of tablets, capsules, powders or syrups, or parenterally in the form of usual sterile solutions for injection.

The pharmaceutical formulations of the invention may be prepared by conventional methods in the art. For example, tablets may be prepared by mixing the active ingredient with ordinary adjuvants and/or diluents and subsequently compressing the mixture in a conventional tableting machine. Examples of adjuvants or diluents comprise: Corn starch, potato starch, talcum, magnesium stearate, gelatine, lactose, gums, and the like. Any other adjuvant or additive colourings, aroma, preservatives etc. may be used provided that they are compatible with the active ingredients.

Solutions for injections may be prepared by solving the active ingredient and possible additives in a part of the solvent for injection, preferably sterile water, adjusting the solution to the desired volume, sterilization of the solution and filling in suitable ampules or vials. Any suitable additive conventionally used in the art may be added, such as tonicity agents, preservatives, antioxidants, etc.

The present compounds and their non-toxic acid addition salts may also be used in combination with other active ingredients, such as neuroleptics, thymoleptics, analgetics etc.

TOXICITY STUDY

In toxicity studies male and female SD rats ranging in weight from 170 g to 200 g were used one day after fasting. Citalopram was dissolved in water and administered orally. Symptoms were observed for one week after citalopram administration. Even when citalopram was administered at a dose of 350 mg/kg no deaths were observed and accordingly it was obvious that citalopram has a very good safety profile.

PHARMACOLOGICAL TESTS**ISCHEMIA-INDUCED HIPPOCAMPAL DEATH IN GERBILS**

The overall objective of the study was to investigate the effects of citalopram on hippocampal lesions induced by ischemia in Mongolian gerbils.

METHODS

Test compounds were administered intraperitoneally to Male Mongolian gerbils 30 min before carotid occlusion. Carotid occlusion time was 5 min. Seven days after recovery, the animals were killed, brains removed, sectioned and surviving neurons were counted along CA1 in the hippocampus.

RESULTS

As is shown in Table 1, citalopram (20 mg/kg) had a weak but non-significant protective effect against neuronal lesions. The higher dose of this compound (40 mg/kg) showed a significant ($p < 0.05$) protective effect against neuronal lesions. Ketamine (100 mg/kg) showed significant ($p < 0.01$) protective effect.

TABLE 1**Effects on Ischemia induced hippocampal neuronal damage in gerbils**

Drug	Dose (mg/kg i.p.)	Gerbils used	Survival neurons/mm		
			mean	S.E.	p
Vehicle	-	10	12.8	2.6	
Citalopram	20	12	38.0	18.5	N.S.
Citalopram	40	11	95.8	27.9	< 0.05
Ketamine	100	8	174.5	25.7	< 0.01

Statistical analysis was carried out according to Dunnett's t-tests vs vehicle group.

PASSIVE AVOIDANCE IN ISCHEMIC GERBILS

The test employed was step-down passive avoidance in gerbils treated with test compounds prior to occlusion of carotid arteries followed by acquisition trial (training phase).

METHODS

Test compounds were administered intraperitoneally to gerbils 30 min prior to carotid occlusion or ketamine was administered intraperitoneally 10 min prior to carotid occlusion. The gerbils were anesthetized with 2% halothane contained in a mixture of 70% nitrogen and 30% oxygen. The right and left common carotid arteries were occluded for 5 min. The gerbils were trained for 5 min in a step-down type passive avoidance chamber

(16x16x20 cm) two days after induced ischemia. Each gerbil was placed on a safety platform (6x16x20 cm) in the chamber and received a series of mild foot shocks (0.1 mA for 3 sec every 6 sec), when the gerbil stepped down to a floor made of metal rods. Gerbils were returned to the safety platform for testing 24 hrs later and their step-down latencies to the grid floor were recorded (max. 60 sec).

RESULTS

Ischemia did not alter step-down latency measured during the training phase. Step-down latency during the training phase were not significantly modified in the gerbils treated with test compound. Step-down latency in the testing phase was significantly decreased between ischemic control and sham operated gerbils. Citalopram (20 mg/kg) and ketamine (120 mg/kg) significantly increased the latency of ischemic gerbils. But the latency in indeloxazine (40 mg/kg) treated gerbils was not significantly different from those in ischemic control gerbils.

TABLE 2
Effect on passive avoidance in ischemic gerbils

Drug	Dose (mg/kg i.p.)	Number of of gerbils	Ischemic treatment	Step-down latency [log(sec)]	
				Mean	S.E.
Saline (sham)	-	15	-	1.471	0.075***
Saline (control)	-	20	+	0.953	0.116
Citalopram	20	7	+	1.386	0.083**
Indeloxazine	40	6	+	1.085	0.244
Ketamine	120	9	+	1.348	0.100*

* : $p < 0.05$, ** : $p < 0.01$, *** : $p < 0.001$ (vs Saline control, by Student's t-test)

BRAIN ISCHEMIA-INDUCED DEATH IN MICE

MATERIALS

Male ICR MICE (Charles River) weighing 30 - 40 g were used after they were fasted for 1 day.

METHOD

Test compounds were administered intraperitoneally to the mice 30 min prior to permanent ligation of bilateral common carotid arteries under conscious condition. Surviving mice were observed over 4 hrs.

RESULTS

Citalopram (30 mg/kg) significantly prevented ischemia-induced death both 2 hrs and 4 hrs after bilateral carotid arterial ligation. Ifenprodil (30 mg/kg), however, did not significantly increase survival rate 4 hrs after ligation, although it showed significantly increased survival rate 2 hrs after the ligation.

TABLE 3

**Effect on ischemia-induced death in
bilateral carotid arterial ligation (BCAL) in mice**

Drug	Dose (mg/kg,p.o.)	Number of mice	Survival rate (%)	
			2 hr after BCAL	4 hr after BCAL
Saline	-	30	23	17
Citalopram	30	30	50*	43*
Saline	-	30	13	7
Ifenprodil	30	30	47**	20

* : $p < 0.05$, ** : $p < 0.01$ (Chi-square test vs each Saline)

KCN-INDUCED COMA IN MICE

METHODS

Male mice (Crj:ICR) weighing 20-30 g were used. The mice were fasted for one day. The drugs, dissolved in saline, were injected intraperitoneally. 30 min after the injection, KCN, dissolved in saline, was injected intravenously at a dose of 1.3 mg/kg. The duration of disappearance of righting reflex was measured as coma time.

RESULTS

Intraperitoneal injection of citalopram significantly reduced coma time at a dose of 10 mg/kg. Indeloxazine at a dose of 20 mg/kg also significantly reduced the coma time.

TABLE 4
Effects of intraperitoneal injection of citalopram on KCN-Induced coma in mice

5

	Drug	Dose (mg/kg, i.p.)	Number of mice	Coma time (sec)	
				Mean	S.E.
	Vehicle	-	16	55.9	8.8
	Citalopram	1.25	15	38.5	4.2
15	Citalopram	2.5	15	33.2	10.0
	Citalopram	5	16	35.0	8.2
	Citalopram	10	16	27.4	6.9*
20	Indeloxazine	20	17	13.8	3.7**

* : $P < 0.05$, ** : $P < 0.01$, Significantly different from values of vehicle control (Dunnett's t-test).

25

CARBON DIOXIDE-INDUCED AMNESIA IN RATS (PASSIVE AVOIDANCE TEST)

The test employed was a one-trial passive avoidance test in rats, using carbon dioxide asphyxiation to induce amnesia.

METHODS

Female Sprague-Dawley (CD) rats (A. Tick & Son Ltd.) in the body weight range 160-180g were used for the study.

The one-trial passive avoidance apparatus consisted of a 32 x 32 x 32 cm chamber with opaque walls and a metal grid floor. A 6 cm wide, 25 cm long runway protruded from the front wall of the chamber. The runway was illuminated while the chamber was dark. When placed on the runway, a rat could enter the chamber through a 6 x 6 cm opening. A scrambled footshock could be delivered through the metal grid floor of the chamber. On the first day of the experiment, the rats received three pre-treatment training trials, during which each animal was placed on the end of the runway and the time taken to enter the chamber ('step-through' latency) was determined.

On the second day of the experiment, groups of 10 animals were treated p.o. with test compound dissolved in saline or with saline.

One hour after administration, an acquisition trial was performed. This was similar to a training trial, except that the rats received a footshock of 1.0 mA for 10 sec. commencing 10 sec after entering the chamber. Immediately after the application of the footshock the animals were subjected to amnesic treatment. Amnesic treatment consisted of placing the rats in a box filled with carbon dioxide until respiratory arrest occurred; the rats were then revived by artificial respiration. 24 Hours after the acquisition trial, a single retrieval trial was given to each rat and the time taken to enter the chamber ('step-through' latency) was recorded for each animal.

If a rat did not enter the chamber within 180 seconds it was taken from the runway.

RESULTS

There were no significant differences between the time of entry ('step-through' latency) of rats dosed with either vehicle, citalopram or piracetam, thus indicating that at oral doses of 40 or 1000 mg/kg, these compounds

did not induce marked muscle incoordination of CNS effects of sufficient magnitude to modify entry times. The amnesic effect of carbon dioxide has been clearly demonstrated in this study. In those rats receiving footshock, but no drug treatment, treatment with carbon dioxide asphyxiation caused a decrease in 'step-through' latency. Oral administration of citalopram at all doses tested caused dose-related increases in the group mean 'step-through' times, which in most cases were statistically significant when compared to the saline-treated control group using Student's t-test. At the 2 highest doses tested (i.e. 20 and 40 mg/kg), a marked and highly significant increase in time was observed.

As expected, piracetam treatment gave statistically significantly longer 'step-through' latencies.

TABLE 5

Effects of oral administration of citalopram
on carbon dioxide-induced amnesia in rats.

Drug	Dose (mg/kg; p.o.)	CO2 Treatment	Number of animals	Latency (sec)
Saline	-	-	10	119.6***
Saline	-	+	10	0.8
Citalopram	5	+	10	31.2
Citalopram	10	+	10	77.2**
Citalopram	20	+	10	114.3***
Piracetam	300	+	10	108.8***

** : $p < 0.01$, *** : $p < 0.001$, significantly different from values of relevant control group (Students t-test).

IN VITRO PLATELET AGGREGATION

METHODS

The test was performed with fresh human platelets. The drugs were diluted in physiological saline to give a solution at a concentration ten times that of the final concentration. The drug was added to the platelets and incubated at 37 °C for 15 min. and then platelet aggregation was induced by the addition of collagen (10 microgram/ml).

RESULTS

Citalopram at a final concentration of 100 microgram/ml inhibited the aggregation of human platelet induced by collagen by 58%. The same concentration of indeloxazine revealed weaker inhibitory effect (8%) than citalopram did on the aggregation by collagen.

EX VIVO PLATELET AGGREGATION

Effect on collagen-induced platelet aggregation using blood of rats administered orally with citalopram was investigated.

MATERIALS

Male Wistar rats (Charles River) in the body weight range 350-400 g were used.

5 METHODS

One hour after oral dosing the rats were lightly anesthetized with ether and blood was collected by cardiac puncture. Nine ml of the blood was mixed with 1 ml of 3.8% sodium citrate and platelet rich plasma (300000 platelets/cmm) was prepared. At the end of the incubation period at 37 °C for 2 min. effects of addition of 10 microgram/ml collagen on platelet aggregation were determined.

RESULTS

A moderate inhibition of collagen-induced aggregation was noted following citalopram at 30 mg/kg (60.4%). At doses of 10 mg/kg only slight inhibition of collagen-induced aggregation was noticed (16.7%).

TABLE 6

Effect on platelet aggregation ex vivo in rats.

Drug	Dose (mg/kg, p.o.)	Number of rats	Mean (%)	S.D. (%)	[% Change from control]
Vehicle	—	12	54.6	27.3	[—]
Citalopram	10	8	45.5	16.0	[-16.7]
Citalopram	30	8	21.6	21.6**	[-60.4]

S.D.: Standard deviation.

Statistical significance using analysis of variance of treatment groups as compared to vehicle treated groups, ** : P<0.01.

It appears from the foregoing Ischemia Induced Hippocampal Death Test that the compound according to the invention tested show improving effect on neuronal lesion. The Passive Avoidance Test in Ischemic gerbils indicate improving effect on memory following to ischemic attack, the Brain Ischemia-Induced Death Test in mice indicate effect on survival rate following to ischemic attack, the KCN-induced Coma test in mice indicate improving effect following to anoxia and the Carbondioxide-Induced Amnesia Test in rats show positive effect on amnesia.

The results of the *in vitro* and the *in vivo* Platelet Aggregation Tests show inhibiting effects on platelet aggregation.

CLINICAL TEST

In a group of depressed patients having concomitant dementia, it was observed that cognitive functions improved after treatment with compound of the general Formula I but not after treatment with placebo. Accordingly, compounds of general Formula I clinically have memory improving effect in patients having dementia which may not only be of cerebrovascular origin but also may result from chronic organic reactions such as neurodegenerative disorders. This is in contradiction to the earlier study of Nyth et al. mentioned above (Nyth, A.L. et al. "The effect of citalopram in dementia disorders", presentation at CINP, August 1988).

FORMULATION EXAMPLES

The following examples show typical formulations of the medicaments manufactured in accordance with the invention

5 1) Tablets containing 0,5 milligrams of citalopram calculated as the free base:

	Citalopram	100 mg
	Lactose	18 mg
10	Potato starch	27 mg
	Saccharose	58 mg
	Sorbitol	3 mg
15	Talcum	5 mg
	Gelatine	2 mg
	Povidone	1 mg
20	Magnesium stearate	0.5 mg

2) Tablets containing 1 milligrams of citalopram calculated as the free base:

25	Citalopram	50 mg
	Lactose	16 mg
	Potato starch	45 mg
30	Saccharose	106 mg
	Sorbitol	6 mg
	Talcum	9 mg
35	Gelatine	4 mg
	Povidone	3 mg
	Magnesium stearate	0.6 mg

40 3) Syrup containing per milliliter:

	Citalopram	5.0 mg
45	Sorbitol	500 mg
	Tragacanth	7 mg
	Glycerol	50 mg
50	Methyl-paraben	1 mg
	Propyl-paraben	0.1 mg
	Ethanol	0.005 ml
55	Water	ad 1 ml

4) Solution for injection containing per milliliter:

Citalopram	50 mg
Acetic acid	17.9 mg
Sterile water	ad 1 ml

5

5) Solution for injection containing per milliliter:


Citalopram	10 mg
Sorbitol	42.9 mg
Acetic acid	0.63 mg
Sodium hydroxide	22 mg
Sterile water	ad 1 ml

10

15

20 Claims

1. Use of a 1-[3-(dimethylamino)propyl]-1-phenylphthalane of the general formula




35

wherein R¹ and R² each are selected from the group consisting of halogen, trifluoromethyl, cyano and R-CO-, wherein R is an alkyl radical with from 1 to 4 C-atoms inclusive, or a pharmaceutically acceptable acid addition salt thereof, for the manufacture of a medicament for the treatment of dementia and cerebrovascular disorders.

40

2. Use of a 1-[3-(dimethylamino)propyl]-1-phenylphthalane of the general formula



55

wherein R¹ and R² each are selected from the group consisting of halogen, trifluoromethyl, cyano and R-CO-, wherein R is an alkyl radical with from 1 to 4 C-atoms inclusive, or a pharmaceutically acceptable acid addition salt thereof, for the manufacture of a medicament for inhibiting platelet aggregation.

3. Use according to claim 1, **characterized in** that the medicament is for the treatment of cerebrovascular disorders caused by cerebral infarction, cerebral hemorrhage, cerebral arteriosclerosis, subarachnoid hemorrhage, cerebral thrombosis, or cerebral embolism.
- 5 4. Use according to claim 3, **characterized in** that the medicament is for the treatment of ischemia.
5. Use according to claim 4, **characterized in** that the medicament is for the treatment of amnesia associated with ischemia.
- 10 6. Use according to claim 3, **characterized in** that the medicament is for the treatment of Vascular or Multi-infarct dementia.
7. Use according to claim 1, **characterized in** that the medicament is for the treatment of dementia of the Alzheimer's type.
- 15 8. Use according to any of claims 1-7, **characterized in** that the 1-dimethylaminopropyl-1-phenyl-phthalane used is citalopram or a pharmaceutically acceptable acid addition salt thereof.

20

25

30

35

40

45

50

55



(11) Publication number : **0 474 580 A3**

(12)

EUROPEAN PATENT APPLICATION

(21) Application number : **91610063.9**

(51) Int. Cl.⁵ : **A61K 31/34**

(22) Date of filing : **16.08.91**

(30) Priority : **06.09.90 DK 2132/90**

(43) Date of publication of application :
11.03.92 Bulletin 92/11

(84) Designated Contracting States :
AT BE CH DE DK FR GB IT LI LU NL SE

(88) Date of deferred publication of search report :
03.06.92 Bulletin 92/23


(71) Applicant : **H. LUNDBECK A/S**
Ottiliavej 7-9
DK-2500 Kobenhavn-Valby (DK)

(72) Inventor : **Tanaka, Yoshiaki**
1-2-10 Nakanishi
Kumagaya-shi, Saitama 360 (JP)
Inventor : **Kobayashi, Naomi**
1643 Kuge
Kumagaya-shi, Saitama 360 (JP)
Inventor : **Kurimoto, Tadashi**
1740-10 Mochida
Gyouda-shi, Saitama 361 (JP)
Inventor : **Ikeda, Yugo**
1-2-2-104 Kakinokizaka
Meguro-ku, Tokyo 152 (JP)

(74) Representative : **Petersen, John Meldahl**
c/o H. Lundbeck A/S Patent Department
Ottiliavej 7-9
DK-2500 Copenhagen-Valby (DK)

(54) Use of 1-[3-(dimethylamino)propyl]-1-phenylphthalenes for the treatment of cerebrovascular disorders.

(57) 1-[3-(dimethylamino)propyl]-1-phenylphthalanes of the general formula



Formula I

wherein R¹ and R² each are selected from the group consisting of halogen, trifluoromethyl, cyano and R-CO-, wherein R is an alkyl radical, or a pharmaceutically acceptable acid addition salt thereof, are useful in the treatment of dementia and cerebrovascular disorders and for inhibiting platelet aggregation in patients in need thereof.



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number

EP 91 61 0063

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.5)
X	FOLIA HAEMATOL. LEIPZIG, vol. 115, no. 4, 1988, pages 475-478, S. HEPTINSTALL et al.: "How can we inhibit 5-HT-induced platelet aggregation and why should we bother?" * Whole article *	2,8	A 61 K 31/34
X	ARCHIVES OF PHARMACOLOGY, vol. 334, no. 4, December 1986, Springer International, pages 341-345, J. BEVAN et al.: "Effects of combinations of 5-hydroxytryptamine receptor antagonists on 5-HT-induced human platelet aggregation" * Page 341, column 2, lines 7-17; page 342, column 1, table I *	2,8	
X	THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 260, no. 12, 25th June 1985, pages 7603-7606, The American Soc. of Biological Chemists US; D. de CHAFFOY DE COURCELLES et al.: "Evidence that phospholipid turnover is the signal transducing system coupled to serotonin-S2 receptor sites" * Page 7603, abstract; page 7605, column 1, line 24 - column 2, line 25 *	2,8	TECHNICAL FIELDS SEARCHED (Int. Cl.5) A 61 K
X	NORD. PSYKIATR. TIDSSKR., vol. 41, no. 6, 1987, pages 423-429, SE; A.-L. NYTH et al.: "Behandling med citalopram vid demens. Normalisering av DST" * Abstract *	1,3,7,8	
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 09-03-1992	Examiner MAIR J.
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	

EPO FORM 150 03.82 (7/90)



European Patent
Office

CLAIMS INCURRING FEES

The present European patent application comprised at the time of filing more than ten claims.

- ☐ All claims fees have been paid within the prescribed time limit. The present European search report has been drawn up for all claims.
- ☐ Only part of the claims fees have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims and for those claims for which claims fees have been paid.
- namely claims:
- ☐ No claims fees have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims.

LACK OF UNITY OF INVENTION

The Search Division considers that the present European patent application does not comply with the requirement of unity of invention and relates to several inventions or groups of inventions.

namely:

see sheet -B-

- ☒ All further search fees have been paid within the fixed time limit. The present European search report has been drawn up for all claims.
- ☐ Only part of the further search fees have been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the inventions in respect of which search fees have been paid.
- namely claims:
- ☐ None of the further search fees has been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the invention first mentioned in the claims.
- namely claims:



European Patent
Office

EUROPEAN SEARCH REPORT

Page 2

Application Number

EP 91 61 0063

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.5)
X	DRUGS OF THE FUTURE, vol. 15, no. 6, June 1990, editor J. R. Prous et al., page 618; "Citalopram" * The whole article *	1,3,7,8	
D,P X	THE BRITISH JOURNAL OF PSYCHIATRY, vol. 157, December 1990, pages 984-901, The Royal College of Psychiatrists; A. L. NYTH et al.: "The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders. A nordic multicentre study" * Page 894, column 1, paragraph 3 - column 2, paragraph 1; pages 899-890, "Discussion" *	1,3,7,8	
D,X	PSYCHOPHARMACOLOGY, supplement to vol. 96, 1988, Abstracts of the XVIth C.I.N.P. Congress, 15th-19th August 1988, Munich, page 45, abstract no. TU24.04, Springer International; C. G. GOTTFRIES: "Dementia disorders and depression in the elderly. Biochemical aspects" * The whole article *	1,3,7,8	
The present search report has been drawn up for all claims			TECHNICAL FIELDS SEARCHED (Int. Cl.5)
Place of search THE HAGUE		Date of completion of the search 09-03-1992	Examiner MAIR J.
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document</p>			

EPF FORM 1501 (01/87) (P0401)



European Patent
Office

EP 91 61 0063

-B-

LACK OF UNITY OF INVENTION

The Search Division considers that the present European patent application does not comply with the requirement of unity of invention and relates to several inventions or groups of inventions, namely:

The application shows non-unity a priori since two distinct inventions are claimed.

1. Claims 1,3-7(completely) and 8(partially) : Use of compounds for the treatment of dementia and cerebro-vascular disorders.
2. Claims 2(complete) and 8(partially) : Use of compounds inhibiting platelet aggregation.